Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland)
Background Intermittent androgen deprivation (IAD) has received increasing attention; however, the current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative efficacy and safety benefits of IAD versus continuous androgen deprivation (CAD) remain unclear....
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2016
|
Subjects: | |
Online Access: | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231404 https://dipot.ulb.ac.be/dspace/bitstream/2013/231404/4/doi_215031.pdf |
id |
ftunivbruxelles:oai:dipot.ulb.ac.be:2013/231404 |
---|---|
record_format |
openpolar |
spelling |
ftunivbruxelles:oai:dipot.ulb.ac.be:2013/231404 2023-05-15T16:52:45+02:00 Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) Schulman, Claude Gómez Veiga, Francisco Baskin-Bey, Edwina López Ruiz, Beatriz Tombal, Bertrand Cornel, Erik Matveev, Vsevolod Tammela, Teuvo Lj J T.L. Schraml, Jan Bensadoun, Henri Warnack, Wolfgang Persad, Raj Salagierski, Marek 2016-04 1 full-text file(s): application/pdf http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231404 https://dipot.ulb.ac.be/dspace/bitstream/2013/231404/4/doi_215031.pdf en eng uri/info:doi/10.1016/j.eururo.2015.10.007 uri/info:pii/S030228381500977X uri/info:scp/84959524015 https://dipot.ulb.ac.be/dspace/bitstream/2013/231404/4/doi_215031.pdf http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231404 1 full-text file(s): info:eu-repo/semantics/openAccess European urology, 69 (4 Néphrologie - urologie Androgen deprivation Continuous androgen deprivation Intermittent androgen deprivation Nonmetastatic Prostate cancer Prostate-specific antigen progression Testosterone info:eu-repo/semantics/article info:ulb-repo/semantics/articlePeerReview info:ulb-repo/semantics/openurl/article 2016 ftunivbruxelles 2022-06-12T21:27:09Z Background Intermittent androgen deprivation (IAD) has received increasing attention; however, the current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative efficacy and safety benefits of IAD versus continuous androgen deprivation (CAD) remain unclear. Objective To add to the knowledge base regarding efficacy and potential benefits, including reduced side effects and improved quality of life (QoL), of IAD versus CAD in patients with nonmetastatic relapsing or locally advanced PCa. Design, setting, and participants A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries. Intervention Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5 mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo. Outcome measurements and statistical analysis The primary end point was time to prostate-specific antigen (PSA) progression while receiving luteinising hormone-releasing hormone agonist, defined as three consecutive increasing PSA values ≥4 ng/ml ≥2 wk apart. Secondary end points included PSA progression-free survival (PFS), overall survival (OS), testosterone levels, performance status, and QoL. Results and limitations A total of 933 patients entered the induction phase; 701 were randomised. The median number of injections administered after randomisation was 12 (range: 1-12) for the CAD group and 3 (range: 1-10) for the IAD group. There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL. A similar number of adverse events was observed in each group; the most common were hot flushes and hypertension. Study limitations include the open-label design and absence of formal testosterone recovery assessment. Conclusions IAD and CAD demonstrated similar efficacy, tolerability, and QoL in men with nonmetastatic PCa. The principal benefit of IAD compared with CAD is a potential cost reduction with ... Article in Journal/Newspaper Iceland DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
institution |
Open Polar |
collection |
DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
op_collection_id |
ftunivbruxelles |
language |
English |
topic |
Néphrologie - urologie Androgen deprivation Continuous androgen deprivation Intermittent androgen deprivation Nonmetastatic Prostate cancer Prostate-specific antigen progression Testosterone |
spellingShingle |
Néphrologie - urologie Androgen deprivation Continuous androgen deprivation Intermittent androgen deprivation Nonmetastatic Prostate cancer Prostate-specific antigen progression Testosterone Schulman, Claude Gómez Veiga, Francisco Baskin-Bey, Edwina López Ruiz, Beatriz Tombal, Bertrand Cornel, Erik Matveev, Vsevolod Tammela, Teuvo Lj J T.L. Schraml, Jan Bensadoun, Henri Warnack, Wolfgang Persad, Raj Salagierski, Marek Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
topic_facet |
Néphrologie - urologie Androgen deprivation Continuous androgen deprivation Intermittent androgen deprivation Nonmetastatic Prostate cancer Prostate-specific antigen progression Testosterone |
description |
Background Intermittent androgen deprivation (IAD) has received increasing attention; however, the current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative efficacy and safety benefits of IAD versus continuous androgen deprivation (CAD) remain unclear. Objective To add to the knowledge base regarding efficacy and potential benefits, including reduced side effects and improved quality of life (QoL), of IAD versus CAD in patients with nonmetastatic relapsing or locally advanced PCa. Design, setting, and participants A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries. Intervention Following a 6-mo induction with leuprorelin acetate (Eligard) 22.5 mg 3-mo depot, patients were randomised to CAD or IAD with leuprorelin for 36 mo. Outcome measurements and statistical analysis The primary end point was time to prostate-specific antigen (PSA) progression while receiving luteinising hormone-releasing hormone agonist, defined as three consecutive increasing PSA values ≥4 ng/ml ≥2 wk apart. Secondary end points included PSA progression-free survival (PFS), overall survival (OS), testosterone levels, performance status, and QoL. Results and limitations A total of 933 patients entered the induction phase; 701 were randomised. The median number of injections administered after randomisation was 12 (range: 1-12) for the CAD group and 3 (range: 1-10) for the IAD group. There were no statistically significant or clinically relevant differences between the groups for time to PSA progression, PSA PFS, OS, mean PSA levels over time, or QoL. A similar number of adverse events was observed in each group; the most common were hot flushes and hypertension. Study limitations include the open-label design and absence of formal testosterone recovery assessment. Conclusions IAD and CAD demonstrated similar efficacy, tolerability, and QoL in men with nonmetastatic PCa. The principal benefit of IAD compared with CAD is a potential cost reduction with ... |
format |
Article in Journal/Newspaper |
author |
Schulman, Claude Gómez Veiga, Francisco Baskin-Bey, Edwina López Ruiz, Beatriz Tombal, Bertrand Cornel, Erik Matveev, Vsevolod Tammela, Teuvo Lj J T.L. Schraml, Jan Bensadoun, Henri Warnack, Wolfgang Persad, Raj Salagierski, Marek |
author_facet |
Schulman, Claude Gómez Veiga, Francisco Baskin-Bey, Edwina López Ruiz, Beatriz Tombal, Bertrand Cornel, Erik Matveev, Vsevolod Tammela, Teuvo Lj J T.L. Schraml, Jan Bensadoun, Henri Warnack, Wolfgang Persad, Raj Salagierski, Marek |
author_sort |
Schulman, Claude |
title |
Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
title_short |
Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
title_full |
Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
title_fullStr |
Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
title_full_unstemmed |
Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: A Phase 3b Randomised Study (Iceland) |
title_sort |
intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (iceland) |
publishDate |
2016 |
url |
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231404 https://dipot.ulb.ac.be/dspace/bitstream/2013/231404/4/doi_215031.pdf |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
European urology, 69 (4 |
op_relation |
uri/info:doi/10.1016/j.eururo.2015.10.007 uri/info:pii/S030228381500977X uri/info:scp/84959524015 https://dipot.ulb.ac.be/dspace/bitstream/2013/231404/4/doi_215031.pdf http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231404 |
op_rights |
1 full-text file(s): info:eu-repo/semantics/openAccess |
_version_ |
1766043135969853440 |